Therapeutic approaches targeting tau pathology have been initially designed to treat AD (Figure 1) (101) or primary tauopathies such as PSP (276), based on a large body of evidence suggesting a strong connection between alterations of tau function and cognitive decline [extensively reviewed in (277)]. Here, MAPT is linked to supranuclear palsy, progressive, 1.